ISO 9001:2015 Certified Company
As clinical research advances in complexity and innovation, the urgency for diversity, equity, and inclusion (DEI) in trials has never been more critical. Beyond regulatory compliance or industry buzzwords, DEI in clinical trials is about making healthcare inclusive, accessible, and effective for everyone.
Whether you’re a pharma company, CRO, or healthcare innovator, embracing digital transformation in clinical trials isn’t optional anymore — it’s the future.
Is your clinical trial ready for ICH E6 (R3)? Discover the key areas to focus on, from risk-based quality management to digital transformation, and ensure compliance with the latest GCP guidelines.
Introduction The landscape of clinical trials is undergoing a seismic shift. No longer confined to rigid protocols and centralized labs, modern clinical research is embracing patient-centric innovation to deliver faster, safer, and more inclusive outcomes. By prioritizing patient empowerment and […]
Here are the top 10 trends in pharmaceutical industry innovations to embrace in 2024 1. Rise in Pharmacovigilance Market: The pharmacovigilance market is expected to grow at a CAGR of 13.6% from 2021 to 2028. Pharmacovigilance is the science of […]
How CROs Can Support Pharmacovigilance and Regulatory Compliance? Pharmacovigilance is the process of monitoring, evaluating, and preventing adverse reactions or any other problems related to medicines. It is an essential part of drug development and post-marketing surveillance, as it ensures […]
DCTs are not a fad, but a trend that is transforming clinical research and patient care. By leveraging technology to make trials more accessible
Pharmacovigilance, an integral field within the realm of drug safety, encompasses a wide range of activities that aim to monitor, assess, and prevent adverse effects associated with medications. By undertaking these endeavors, pharmacovigilance ensures that the benefits provided by a […]
Clinical trials happen in several phases during which different questions are asked.
Each phase builds on the results of previous phases
ADRs refer to harmful or unintended reactions caused by the use of medications or medical treatments. They range from mild side effects to severe and life-threatening events
Vigilare Biopharma Pvt. Ltd.
Plot no 52,57,1st Floor,
Opp:Prerana Hospital
Balajinagar, Kukatpally,
Hyderabad Telangana,
India -500072
Mail us: info@vigilarebp.com
Novel Techpark,Ground floor, #46, Hosur Rd, Krishna Reddy Industrial Area, Hosapalaya, Bengaluru – 560068.
Mail us: info@vigilarebp.com
8910 University Center Lane, Suite 400
San Diego, CA 92122
Mail us: info@vigilarebp.com